In this article
Drug Mechanism & Hypothesis
Acalabrutinib is a second-generation tyrosine kinase (BTK) inhibitor, a newer drug that can improve the survival of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).
The researchers believe that BTK inhibitors combined with modified CD20 antibody drugs (such as Obinutuzumab) can improve the speed and depth of Acalabrutinib treatment by responding to further sensitized cancer cells.
Clinical Trial Data & Results
In the Phase 1 b / II clinical trial, the researchers evaluated the effect of the combined therapy of Acalabrutinib and Obinutuzumab at the Ohio State University Comprehensive Cancer Center-James Cancer Hospital-Richard Research Center (OSUCCC-James), convening 45 relapsed / refractory or CLL patients who have never received treatment.
Overall, the combination therapy of and Obinutuzumab is well tolerated, and the response rate has improved over time.
Among patients who had not received any treatment, the overall response rate was 95%. The median follow-up period was 17.8 months. The overall survival rate (OS) of patients with relapsed / refractory CLL was 92%, with a median follow-up period of 21 months.
Expert Insight & Conclusion
OSUCCC-James. Associate Professor and first author Jennifer Woyach said that despite the progress made in the treatment of CLL in recent years, the need for additional treatment options is still urgent.
The overall effectiveness of the Acalabrutinib trial emphasizes that this clinical study may have a potential impact on the management of CLL.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Susan Hau
Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy. Hau's expertise lies in cancer cell biolo…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.